New drug targets fatty liver in early human trial

NCT ID NCT05648214

First seen Jan 11, 2026 · Last updated Jun 12, 2026 · Updated 24 times

Summary

This study tests an experimental drug called ALN-PNP for people with a type of fatty liver disease (MASLD) who have a specific gene variant. It is a first-in-human trial, meaning it is the first time this drug is given to people. The main goals are to check if the drug is safe, tolerable, and how it works in the body. The study includes healthy volunteers and people with MASLD, and will measure changes in liver fat.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • California Clinical Trials Medical Group

    COMPLETED

    Glendale, California, 91206, United States

  • Genoma Research Group, Inc

    RECRUITING

    Miami, Florida, 33173, United States

  • Med Research of Florida, LLC

    RECRUITING

    Miami, Florida, 33186, United States

  • Pioneer Research Solutions

    RECRUITING

    Houston, Texas, 77099, United States

  • Tandem Clinical Research

    RECRUITING

    Marrero, Louisiana, 70072, United States

  • Velocity Clinical research

    RECRUITING

    Los Angeles, California, 90057, United States

Conditions

Explore the condition pages connected to this study.